KRAS and metastatic neoplasm: Finally, in regard to the timing of metastatic disease, Sakai et al. found that in a cohort of 101 patients, KRAS mutation was independently associated with worse overall survival for patients with synchronous CRLM but not in those with metachronous disease (synchronous disease, HR 4.316, p < 0.001) [27].